The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.本發明係關於結合人類血管生成素-2(Ang2)之抗體,其可單獨及與VEGF路徑抑制劑組合用於治療癌症,尤其由VEGFR2及Ang2驅動之癌症,包含胃癌、肝細胞癌、卵巢癌、結腸直腸癌及乳癌。